home / stock / ampe / ampe news

AMPE News and Press, Ampio Pharmaceuticals Inc. From 12/02/20

Stock Information
Company Name: Ampio Pharmaceuticals Inc.
Stock Symbol: AMPE
Market: OTC
Website: ampiopharma.com
Menu
AMPE AMPE Quote AMPE Short AMPE News AMPE Articles AMPE Message Board
Get AMPE Alerts

News, Short Squeeze, Breakout and More Instantly...
AMPE - Ampio Pharmaceuticals to complete enrollment in early-stage with inhaled Ampion in COVID-19 patients

Ampio Pharmaceuticals ([[AMPE]] +6.1%) says that its Phase I trial of inhaled Ampion (AP-014) in COVID-19 patients proceeded to full open enrollment following clearance by the Safety Monitoring Committee ((SMC)), which found Ampion to be safe and well-tolerated after revie...
AMPE - Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress

Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress ENGLEWOOD, Colo. , Dec. 2, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the ad...

AMPE - Ampio updates on Phase 1 study with inhaled Ampion in COVID-19 patients

Ampio ([[AMPE]] +0.2%) provides following update on clinical trials.Phase I trial of inhaled Ampion (AP-014), the third of three initial safety groups of patients have completed five days of treatment and three days of follow up for Safety Monitoring Committee review, as inhalation ...

AMPE - Ampio Updates Regulatory and Clinical Trial Events

Ampio Updates Regulatory and Clinical Trial Events PR Newswire ENGLEWOOD, Colo., Nov. 25, 2020 ENGLEWOOD, Colo. , Nov. 25, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of i...
AMPE - Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress

Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress PR Newswire ENGLEWOOD, Colo., Nov. 17, 2020 ENGLEWOOD, Colo. , Nov. 17, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE),&...

AMPE - Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress

Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress PR Newswire ENGLEWOOD, Colo., Nov. 10, 2020 ENGLEWOOD, Colo. , Nov. 10, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), ...

AMPE - Ampio Pharmaceuticals, Inc. (AMPE) CEO on Q3 2020 Earnings Results - Conference Call Transcript

Ampio Pharmaceuticals, Inc. (AMPE) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Participants Joe Hassett - Investor Relations, Gregory FCA Michael Macaluso - Founder, Chairman and Chief Executive Officer Dan Stokely - Chief Financial Officer Laura Goldberg - Vice President, Qu...
AMPE - Ampio Pharmaceuticals reports Q3 results

Ampio Pharmaceuticals (AMPE): Q3 Net loss of $3.4M.Cash and cash equivalents of $9.4MPress Release For further details see: Ampio Pharmaceuticals reports Q3 results

AMPE - Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results

Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results PR Newswire ENGLEWOOD, Colo., Nov. 5, 2020 ENGLEWOOD, Colo. , Nov. 5, 2020 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceuti...

AMPE - Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th

Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th Will Provide Business Update and Review Third Quarter Financial Results PR Newswire ENGLEWOOD, Colo., Nov. 2, 2020 ENGLEWOOD, Colo. , Nov. 2, 2020 /PRNewswire/ -- Ampio Pharmaceuticals (N...
Previous 10 Next 10